Outlook Therapeutics (OTLK) Net Income towards Common Stockholders: 2015-2024
Historic Net Income towards Common Stockholders for Outlook Therapeutics (OTLK) over the last 10 years, with Sep 2024 value amounting to -$75.4 million.
- Outlook Therapeutics' Net Income towards Common Stockholders rose 3.28% to -$9.9 million in Q3 2020 from the same period last year, while for Sep 2020 it was -$48.9 million, marking a year-over-year decrease of 35.61%. This contributed to the annual value of -$75.4 million for FY2024, which is 27.78% down from last year.
- According to the latest figures from FY2024, Outlook Therapeutics' Net Income towards Common Stockholders is -$75.4 million, which was down 27.78% from -$59.0 million recorded in FY2023.
- Over the past 5 years, Outlook Therapeutics' Net Income towards Common Stockholders peaked at -$48.9 million during FY2020, and registered a low of -$75.4 million during FY2024.
- Its 3-year average for Net Income towards Common Stockholders is -$66.8 million, with a median of -$66.1 million in 2022.
- Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first crashed by 35.61% in 2020, then grew by 10.70% in 2023.
- Over the past 5 years, Outlook Therapeutics' Net Income towards Common Stockholders (Yearly) stood at -$48.9 million in 2020, then declined by 8.78% to -$53.2 million in 2021, then dropped by 24.24% to -$66.1 million in 2022, then increased by 10.70% to -$59.0 million in 2023, then dropped by 27.78% to -$75.4 million in 2024.